New Drug Helps Drinkers Stay on the Wagon
March 31, 2000 (Atlanta) -- For drinkers who want to quit, there's a new
drug called acamprosate that curbs the urge to take that first drink -- the one
that so often leads to full relapse. What's more, it seems to be safe for the
vast majority of alcoholics, including those with liver problems and other
Though still awaiting FDA approval, the drug has shown promising results in
several European studies and in a large clinical trial that just concluded here
in the U.S.
Barbara Mason, PhD, the trial's principal researcher, describes acamprosate
as an exciting, safe option. "It's not magic that will get an unmotivated,
drinking person to be transformed," she tells WebMD. "It isn't
Tinkerbell's wand. But in the motivated patient, it does give added benefit
beyond the behavioral therapy which has traditionally been available." At
the University of Miami, Mason is professor of psychiatry and behavioral
sciences and director of the division of substance abuse.
For the six-month trial, Mason enrolled a group of patients that mirrored
the alcoholic population -- very diverse in terms of ethnicity, age, severity
of disorder, liver problems, use of other addictive substances, and geographic
location. Most had been drinking since age 15, with symptoms of drinking
problems (missing work, etc.) first showing as they got closer to age 30.
One-third were women, also mirroring alcoholism trends in the general
The trial was done in medical centers and community-based treatment settings
in 21 cities across the U.S., with about 600 men and women participating. The
participants received either 2 g of acamprosate or a placebo. A small number
received an exploratory 3 g of acamprosate. Blood tests were used to monitor
the volunteers' compliance in taking the drug.
Although she is still putting the data together, Mason says that preliminary
results are similar to what the European trials showed -- that with
acamprosate, abstinence from alcohol increased by 10-25%. The 3 g dose was also
well tolerated and showed linear dose response, meaning the higher the dosage,
the better the results, says Mason. "But again, that's exploratory,"
A European trial published in The Lancet last May involved almost 450
people with chronic or episodic alcohol dependency. By the end of the trial, 41
patients taking acamprosate remained abstinent, vs. 18 receiving a placebo.
Those in the acamprosate group who had relapses remained abstinent longer than
their counterparts in the placebo group.
Acamprosate is the third medication aimed at helping alcoholics curb their
habit. Antabuse (disulfiram), which has been available for about 40 years,
works by blocking alcohol metabolism. It therefore causes a very toxic reaction
when an alcoholic takes a drink.
Developed more recently, ReVia (naltrexone) is an opioid blocker that binds
with the pleasure receptors in the brain so alcohol doesn't overstimulate them.
"Naltrexone blocks the rewarding effects of alcohol," Mason says.